Global weight loss drug leader to announce Q3 performance GLP-1 drug market potential is expected to continue to release. On November 2nd, American weight loss drug leader Novo Nordisk will announce Q3 performance. Previously, Novo Nordisk's official website announced that based on a fixed exchange rate (CER), sales for the first nine months of 2023 increased by 33% year-on-year, and operating profit increased by 37% year-on-year. In addition, the company has raised its annual sales and operating profit expectations, with an expected annual sales growth of 32% to 38% and operating profit growth of 40% to 46%.